Literature DB >> 30632020

Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.

Ulrike Nitz1,2, Oleg Gluz3,4, Matthias Christgen5, Ronald E Kates1, Michael Clemens6, Wolfram Malter7, Benno Nuding8, Bahriye Aktas9, Sherko Kuemmel10, Toralf Reimer11, Andrea Stefek12, Fatemeh Lorenz-Salehi13, Petra Krabisch14, Marianne Just15, Doris Augustin16, Cornelia Liedtke1,17, Calvin Chao18, Steven Shak18, Rachel Wuerstlein1,19, Hans H Kreipe5, Nadia Harbeck1,19.   

Abstract

The article Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial, written by Ulrike Nitz, Oleg Gluz, Matthias Christgen, Ronald E. Kates, Michael Clemens, Wolfram Malter, Benno Nuding, Bahriye Aktas, Sherko Kuemmel, Toralf Reimer, Andrea Stefek, Fatemeh Lorenz-Salehi, Petra Krabisch, Marianne Just, Doris Augustin, Cornelia Liedtke, Calvin Chao, Steven Shak, Rachel Wuerstlein, Hans H. Kreipe, Nadia Harbeck, was originally published electronically on the publisher's internet portal (currently SpringerLink) on June 29, 2017 without open access.With the author(s)' decision to opt for Open Choice the copyright of the article changed on January 6, 2019 to
© The Author(s) 2017 and the article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, a link is provided to the Creative Commons license and any changes made are indicated. The original article has been corrected.

Entities:  

Year:  2019        PMID: 30632020      PMCID: PMC6491403          DOI: 10.1007/s10549-018-05105-8

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


Correction to: Breast Cancer Res Treat (2017) 165:573–583 10.1007/s10549-017-4358-6

The article Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial, written by Ulrike Nitz, Oleg Gluz, Matthias Christgen, Ronald E. Kates, Michael Clemens, Wolfram Malter, Benno Nuding, Bahriye Aktas, Sherko Kuemmel, Toralf Reimer, Andrea Stefek, Fatemeh Lorenz-Salehi, Petra Krabisch, Marianne Just, Doris Augustin, Cornelia Liedtke, Calvin Chao, Steven Shak, Rachel Wuerstlein, Hans H. Kreipe, Nadia Harbeck, was originally published electronically on the publisher’s internet portal (currently SpringerLink) on June 29, 2017 without open access.With the author(s)’ decision to opt for Open Choice the copyright of the article changed on January 6, 2019 to © The Author(s) 2017 and the article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, a link is provided to the Creative Commons license and any changes made are indicated. The original article has been corrected.
  1 in total

Review 1.  Are we closer to being able to select patients with node-positive hormone receptor-positive breast cancer who can safely omit chemotherapy?

Authors:  Caitlin Taylor; Jane Meisel; Kevin Kalinsky
Journal:  Ther Adv Med Oncol       Date:  2022-03-26       Impact factor: 8.168

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.